Clinical Trials Sponsored by Galapagos NV

Total 333 results

Galapagos NV

Completed

A Study in Healthy Male Volunteers to Test How the Test Medicine GLPG1972 is Taken up by the Body When Given by Mouth and Into the Vein as an Injection

Healthy

United Kingdom
Galapagos NV

Completed

A Study to Evaluate the Effects of a Single and Multiple Oral Doses of GLPG3121 in Adult, Healthy, Male Subjects

Healthy

Belgium
Galapagos NV

Completed

A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without GLPG2737 in Patients With Cystic Fibrosis. (FALCON)

Cystic Fibrosis

Belgium, Bulgaria, Germany, Greece, Netherlands, Serbia, Sweden, United Kingdom
Galapagos NV

Completed

A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG3067 in Healthy Subjects.

Healthy

Belgium
Galapagos NV

Completed

A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2451 in Healthy Male Subjects

Healthy

Belgium
Galapagos NV

Completed

This is a Study to Evaluate the Effect of Aging of Multiple Doses of GLPG1205 in Healthy Subjects

Healthy | Elderly

Belgium
Galapagos NV

Completed

First-in-Human Single and Multiple Dose of GLPG1972

Healthy

Belgium
Galapagos NV

Completed

First-in-Human Single and Multiple Dose of GLPG2222

Healthy

Belgium
Galapagos NV

Completed

A Phase I, Open Interaction Study Between GLPG1837 and Midazolam in Healthy Male Subjects

Healthy

Belgium
Galapagos NV

Completed

Oral Bioavailability of Solid Formulation of GLPG1205 With and Without Food

Healthy

Belgium
Galapagos NV

Completed

First-in-Human Single and Multiple Dose of GLPG1205

Healthy

Belgium
Galapagos NV

Completed

Dose-ranging Study With GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients

Rheumatoid Arthritis

Hungary, Moldova, Republic of, Russian Federation, Ukraine
Galapagos NV

Completed

Investigation of the Pharmacokinetics and Metabolism of GLPG0634 in Healthy Male Subjects

Healthy

United Kingdom
Galapagos NV

Completed

Single and Multiple Dose Pharmacokinetics of GLPG0634 in Elderly Healthy Subjects

Healthy

Belgium
Galapagos NV

Completed

Safety and Preliminary Efficacy of GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients

Rheumatoid Arthritis

Moldova, Republic of
Galapagos NV

Completed

First-in-Human Single Ascending and Multiple Dose of GLPG0259

Healthy

Belgium
Galapagos NV

Completed

First-in-Human Single Ascending and Multiple Dose of GLPG0778

Healthy

Belgium
Galapagos NV

Completed

First-in-Human Single Ascending and Multiple Dose of GLPG0634

Healthy

Belgium
Galapagos NV

Completed

Pharmacokinetics/Pharmacodynamics (PK/PD) of Multiple Oral Doses of GLPG0555 in Healthy Subjects

Healthy

Belgium
Galapagos NV

Completed

First-in-Human Single Ascending and Multiple Dose of GLPG0555

Healthy

Belgium
Galapagos NV

Recruiting

A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis (GALARISSO)

Dermatomyositis

United States, Belgium, Italy, Chile, Spain, Poland, United Kingdom, Bulgaria, Romania, Colombia, Croatia, Czechia, France, Argentina
Galapagos NV

Active, not recruiting

A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis (OLINGUITO)

Axial Spondyloarthritis

Belgium, Korea, Republic of, Greece, Taiwan, France, Romania, Germany, Netherlands, Italy, Philippines, United Kingdom, Hungary, Estonia, South Africa, Bulgaria, Spain, Croatia, Czechia, Poland, Lithuania
Galapagos NV

Active, not recruiting

Prospective Observational Study of Filgotinib in Participants With Rheumatoid Arthritis in France (PARROTFISH)

Rheumatoid Arthritis

France
Galapagos NV

Completed

Relative Bioavailability and Effect of Food Study With an Oral Mini-tablet Formulation of Filgotinib in Healthy Subjects

Bioavailability

Canada
Galapagos NV

Terminated

A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS) (GLIDER)

Primary Sjögren Syndrome

Germany, Greece, Poland, Hungary, Ukraine
Galapagos NV

Terminated

A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Autosomal Dominant Polycystic Kidney Disease

Belgium, Netherlands, Italy, Spain, Czechia, Germany, Poland
Galapagos NV

Completed

Drug-drug Interaction Study With GLPG3667 and Itraconazole in Healthy Subjects

Healthy

Canada
Galapagos NV

Terminated

An Open-label, Long-term Extension Study With Filgotinib in Active Psoriatic Arthritis.

Psoriatic Arthritis

Estonia, Belgium, Bulgaria, Czechia, Poland, Spain, Ukraine
Galapagos NV

Terminated

A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis

Systemic Sclerosis

Spain, United States, Belgium, United Kingdom, Italy
Galapagos NV

Completed

A Study to Evaluate How Well Single and Multiple Doses of GLPG3667 Are Tolerated in Healthy, Adult Subjects

Healthy

Belgium
Galapagos NV

Completed

Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects

Healthy

Canada
Galapagos NV

Terminated

A Study Evaluating the Effects of GLPG3970 Given as Oral Treatment for 12 Weeks in Adults With Systemic Lupus Erythematosus (TAPINOMA)

Systemic Lupus Erythematosus

Spain, Bulgaria, Moldova, Republic of, Poland, Ukraine
Galapagos NV

Completed

Drug-drug Interaction Study With GLPG3970 and Sulfasalazine in Adult, Healthy Subjects

Healthy

United States
Galapagos NV

Completed

A Study Evaluating the Effects of GLPG3667 Given as an Oral Treatment for 4 Weeks in Adults With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

Poland, Slovakia, Bulgaria
Galapagos NV

Terminated

A Study in Healthy Male Volunteers Investigating the Safety, Absorption and Elimination of Single Doses of GLPG4059

Healthy

Netherlands
Galapagos NV

Completed

A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis (NOVESA)

Systemic Sclerosis

United States, Belgium, Spain, Germany, United Kingdom, Italy
Galapagos NV

Completed

A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3667

Healthy

Belgium
Galapagos NV

Terminated

A Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics (PK)/Pharmacodynamics (PD) of MOR106 in Subjects With Moderate to Severe Atopic Dermatitis (IGUANA)

Atopic Dermatitis

Germany, Hungary, Poland, Slovakia, United Kingdom
Galapagos NV

Completed

A Study to Assess Efficacy and Safety of Filgotinib in Ankylosing Spondylitis (TORTUGA)

Ankylosing Spondylitis

Belgium, Bulgaria, Czechia, Estonia, Poland, Spain, Ukraine
Galapagos NV

Completed

A Study in Healthy Male Volunteers to Look at How the Test Medicine GLPG1690 is Taken up by the Body When Doses of Itraconazole and Voriconazole Are Given to Healthy Volunteers

Healthy

United Kingdom
Galapagos NV

Completed

GLPG2737 on Top of Orkambi in Subjects With Cystic Fibrosis (PELICAN)

Cystic Fibrosis

Germany
Galapagos NV

Completed

A Study to Assess Efficacy and Safety of Filgotinib in Active Psoriatic Arthritis (EQUATOR)

Psoriatic Arthritis

Estonia, Belgium, Bulgaria, Czechia, Poland, Spain, Ukraine
Galapagos NV

Completed

Pharmacokinetics of GLPG2737 in Male Subjects With Cystic Fibrosis

Cystic Fibrosis

Belgium
Galapagos NV

Completed

A Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic Fibrosis

Cystic Fibrosis

Ireland, United Kingdom, Belgium, Australia, Czechia, Germany
Galapagos NV

Completed

Study to Compare Bioavailability of GLPG1972 Given as 2 Different Tablet Formulations Versus an Oral Solution

Healthy

Belgium
Galapagos NV

Completed

Study of GLPG1837 in Subjects With Cystic Fibrosis (G551D Mutation) (SAPHIRA1)

Cystic Fibrosis

United Kingdom, Australia, Ireland, Germany, Czech Republic
Galapagos NV

Completed

Study of GLPG1837 in Subjects With Cystic Fibrosis (S1251N Mutation) (SAPHIRA2)

Cystic Fibrosis

Belgium, Netherlands
Galapagos NV

Completed

Oral Bioavailability of Solid Formulation of GLPG1837 With and Without Food

Healthy

Belgium
Galapagos NV

Completed

First-in-Human Single and Multiple Dose of GLPG1690

Healthy

Belgium
Galapagos NV

Completed

Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of GLPG0974 in Subjects With Ulcerative Colitis

Ulcerative Colitis

Belgium, Czech Republic, Slovakia, Latvia

3

Subscribe